Ustekinumab
- Generic Name
- Ustekinumab
- Brand Names
- Stelara, Pyzchiva, Uzpruvo, Wezenla, Steqeyma, Otulfi, Fymskina, Eksunbi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 815610-63-0
- Unique Ingredient Identifier
- FU77B4U5Z0
- Background
Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic disease-modifying anti-rheumatic drug (bDMAR...
- Indication
Ustekinumab is indicated for the management of moderate to severe plaque psoriasis in patients 6 years of age and older who are candidates for phototherapy or systemic therapy. In adult patients, it is also indicated for the management of active psoriatic arthritis (PsA) alone or in combination with methotrexate, moderately to severely active Crohn’s disease...
- Associated Conditions
- Severe Plaque psoriasis, Ulcerative Colitis, Active Severe, Active Psoriatic arthritis, Moderate Plaque psoriasis, Moderate Ulcerative colitis, Moderate, active Crohn´s Disease, Severe, active Crohn´s Disease
- Associated Therapies
- -
Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)
- Conditions
- Interventions
- First Posted Date
- 2014-12-18
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 149
- Registration Number
- NCT02319759
A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab
- Conditions
- Interventions
- First Posted Date
- 2014-07-29
- Last Posted Date
- 2017-09-12
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 872
- Registration Number
- NCT02203032
Vascular Inflammation in Psoriasis-Ustekinumab (VIP-U)
- Conditions
- Interventions
- First Posted Date
- 2014-07-10
- Last Posted Date
- 2019-08-15
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 43
- Registration Number
- NCT02187172
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
A Pharmacokinetic Study of Single-Dose Intravenous Ustekinumab Delivered in 2 Different Liquid in Vial Formulations
- First Posted Date
- 2014-06-05
- Last Posted Date
- 2016-03-22
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 140
- Registration Number
- NCT02156375
Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2014-05-22
- Last Posted Date
- 2023-05-16
- Lead Sponsor
- University of Athens
- Target Recruit Count
- 200
- Registration Number
- NCT02144857
- Locations
- 🇬🇷
Attikon Hospital, Athens, Greece
Pilot Clinical Trial of Ustekinumab in Patients With New-onset T1D
- First Posted Date
- 2014-04-21
- Last Posted Date
- 2016-05-25
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 20
- Registration Number
- NCT02117765
- Locations
- 🇨🇦
BC Diabetes, Vancouver, British Columbia, Canada
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
- Conditions
- Interventions
- First Posted Date
- 2014-04-03
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 200
- Registration Number
- NCT02103361
- Locations
- 🇺🇸
University of California, San Diego, La Jolla, California, United States
BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab
- First Posted Date
- 2014-02-04
- Last Posted Date
- 2016-09-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 166
- Registration Number
- NCT02054481
- Locations
- 🇺🇸
1311.2.10011 Boehringer Ingelheim Investigational Site, Houston, Texas, United States
🇸🇪1311.2.46001 Boehringer Ingelheim Investigational Site, Stockholm, Sweden
🇫🇷1311.2.33005 Boehringer Ingelheim Investigational Site, Marseille, France
A Study of Ustekinumab (STELARA®) in Adult Japanese Participants With Severe Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2013-09-18
- Last Posted Date
- 2016-03-09
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 79
- Registration Number
- NCT01945086
Economic Evaluation of Systemic Treatments for Moderate-to-severe Psoriasis
- Conditions
- First Posted Date
- 2013-03-18
- Last Posted Date
- 2017-08-11
- Lead Sponsor
- Jochen Schmitt.
- Target Recruit Count
- 1
- Registration Number
- NCT01812954
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.